Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

NICE Recommends Biosimilar Infliximab For RA

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, looks set to recommend biosimilar versions of Merck's Remicade (infliximab) – Napp's Remsima and Hospira's Inflectra – as well as the originator, for some NHS patients with rheumatoid arthritis.



Related Companies